Magic mushroom compound tested as opioid addiction aid
NCT ID NCT04161066
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study is testing whether adding two doses of psilocybin (the active ingredient in magic mushrooms) to standard buprenorphine/naloxone treatment is safe for adults with opioid use disorder. Ten participants will receive psilocybin along with counseling, while researchers monitor side effects, withdrawal symptoms, and changes in cravings. The goal is to see if psilocybin can safely support existing medication-assisted treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
psilocybin
What this could lead to
If it works, this could point toward a new way to help people with opioid use disorder stay in treatment and reduce cravings.
What could go wrong
This is a very small, early-phase safety study with only 10 participants, so results may not apply widely. Psilocybin can cause intense psychological effects and is not yet proven effective for this condition.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OPIOID USE DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Wisconsin
RECRUITINGMadison, Wisconsin, 53705, United States
Contact